Nectar Lifesciences Limited (NECLIFE.BO)
INR 44.02
(0.0%)
INR 44.02
(0.0%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 16.84 Billion INR | 10.63% |
| 2022 | 15.23 Billion INR | -8.7% |
| 2021 | 16.68 Billion INR | 8.13% |
| 2020 | 15.43 Billion INR | -34.78% |
| 2019 | 23.66 Billion INR | -14.97% |
| 2018 | 27.82 Billion INR | 48.32% |
| 2017 | 18.76 Billion INR | 14.15% |
| 2016 | 16.43 Billion INR | -1.91% |
| 2015 | 16.75 Billion INR | 2.0% |
| 2014 | 16.42 Billion INR | 0.31% |
| 2013 | 16.37 Billion INR | 0.8% |
| 2012 | 16.24 Billion INR | 24.67% |
| 2011 | 13.03 Billion INR | 23.48% |
| 2010 | 10.55 Billion INR | 24.79% |
| 2009 | 8.45 Billion INR | 8.44% |
| 2008 | 7.79 Billion INR | 0.71% |
| 2007 | 7.74 Billion INR | 65.18% |
| 2006 | 4.68 Billion INR | 61.39% |
| 2005 | 2.9 Billion INR | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q1 | 3.59 Billion INR | -18.6% |
| 2023 Q2 | 3.97 Billion INR | 0.97% |
| 2023 FY | 16.85 Billion INR | 10.63% |
| 2023 Q1 | 3.94 Billion INR | 1.6% |
| 2023 Q4 | 4.41 Billion INR | -2.39% |
| 2023 Q3 | 4.52 Billion INR | 13.62% |
| 2022 Q4 | 3.87 Billion INR | 12.72% |
| 2022 FY | 15.23 Billion INR | -8.7% |
| 2022 Q1 | 4.03 Billion INR | -15.37% |
| 2022 Q2 | 3.88 Billion INR | -3.57% |
| 2022 Q3 | 3.44 Billion INR | -11.46% |
| 2021 Q4 | 4.76 Billion INR | 7.5% |
| 2021 FY | 16.68 Billion INR | 8.13% |
| 2021 Q3 | 4.42 Billion INR | 21.51% |
| 2021 Q2 | 3.64 Billion INR | -5.32% |
| 2021 Q1 | 3.85 Billion INR | 10.17% |
| 2020 Q4 | 3.49 Billion INR | -7.39% |
| 2020 Q1 | 3.89 Billion INR | -31.01% |
| 2020 Q3 | 3.77 Billion INR | -11.57% |
| 2020 Q2 | 4.26 Billion INR | 9.54% |
| 2020 FY | 15.43 Billion INR | -34.78% |
| 2019 Q1 | 5.75 Billion INR | -27.69% |
| 2019 Q3 | 6.47 Billion INR | 12.04% |
| 2019 FY | 23.66 Billion INR | -14.97% |
| 2019 Q4 | 5.64 Billion INR | -12.84% |
| 2019 Q2 | 5.78 Billion INR | 0.52% |
| 2018 Q3 | 7.32 Billion INR | 1.21% |
| 2018 Q1 | 5.3 Billion INR | 0.0% |
| 2018 Q4 | 7.95 Billion INR | 8.6% |
| 2018 FY | 27.82 Billion INR | 48.32% |
| 2018 Q2 | 7.23 Billion INR | 36.38% |
| 2017 FY | 18.76 Billion INR | 14.15% |
| 2016 FY | 16.43 Billion INR | -1.91% |
| 2015 Q3 | - INR | 0.0% |
| 2015 FY | 16.75 Billion INR | 2.0% |
| 2014 FY | 16.42 Billion INR | 0.31% |
| 2014 Q3 | - INR | 0.0% |
| 2013 FY | 16.37 Billion INR | 0.8% |
| 2012 FY | 16.24 Billion INR | 24.67% |
| 2011 FY | 13.03 Billion INR | 23.48% |
| 2010 FY | 10.55 Billion INR | 24.79% |
| 2009 FY | 8.45 Billion INR | 8.44% |
| 2008 FY | 7.79 Billion INR | 0.71% |
| 2007 FY | 7.74 Billion INR | 65.18% |
| 2006 FY | 4.68 Billion INR | 61.39% |
| 2005 FY | 2.9 Billion INR | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Ajanta Pharma Limited | 42.08 Billion INR | 59.986% |
| Amrutanjan Health Care Limited | 4.21 Billion INR | -299.802% |
| Sigachi Industries Limited | 3.98 Billion INR | -322.123% |
| Bal Pharma Limited | 3.39 Billion INR | -396.459% |
| Ind-Swift Laboratories Limited | 12.8 Billion INR | -31.477% |
| Medico Remedies Limited | 1.44 Billion INR | -1062.074% |
| Lasa Supergenerics Limited | 1.04 Billion INR | -1514.114% |
| Venus Remedies Limited | 5.91 Billion INR | -184.739% |
| Sun Pharma Advanced Research Company Limited | 755.45 Million INR | -2129.24% |
| Alpa Laboratories Limited | 1.08 Billion INR | -1448.741% |
| Shilpa Medicare Limited | 11.51 Billion INR | -46.238% |
| Aarti Drugs Limited | 25.28 Billion INR | 33.398% |
| Lupin Limited | 200.1 Billion INR | 91.584% |
| Aurobindo Pharma Limited | 287.04 Billion INR | 94.133% |
| Zydus Lifesciences Limited | 190.21 Billion INR | 91.146% |
| Windlas Biotech Limited | 6.3 Billion INR | -166.91% |
| Suven Life Sciences Limited | 116.92 Million INR | -14302.637% |
| Eris Lifesciences Limited | 20.09 Billion INR | 16.179% |
| Valiant Laboratories Limited | 1.82 Billion INR | -825.031% |
| J. B. Chemicals & Pharmaceuticals Limited | 34.84 Billion INR | 51.665% |
| Solara Active Pharma Sciences Limited | 12.38 Billion INR | -35.99% |
| Ipca Laboratories Limited | 76.22 Billion INR | 77.906% |
| Bliss GVS Pharma Limited | 7.7 Billion INR | -118.643% |
| Achyut Healthcare Limited | 61.36 Million INR | -27341.966% |
| Sun Pharmaceutical Industries Limited | 484.96 Billion INR | 96.527% |
| Bajaj HealthCare Limited | 4.73 Billion INR | -255.729% |
| RPG Life Sciences Limited | 5.82 Billion INR | -189.337% |
| Mankind Pharma Limited | 103.34 Billion INR | 83.705% |
| Laurus Labs Limited | 50.01 Billion INR | 66.33% |
| Piramal Pharma Limited | 81.71 Billion INR | 79.39% |
| Syncom Formulations (India) Limited | 2.59 Billion INR | -549.614% |
| Torrent Pharmaceuticals Limited | 106.05 Billion INR | 84.121% |
| Alembic Pharmaceuticals Limited | 61.12 Billion INR | 72.447% |
| Glenmark Pharmaceuticals Limited | 118.13 Billion INR | 85.744% |
| Unichem Laboratories Limited | 16.57 Billion INR | -1.609% |
| Sequent Scientific Limited | 13.69 Billion INR | -22.95% |
| Novartis India Limited | 3.35 Billion INR | -402.607% |
| Wanbury Limited | 5.75 Billion INR | -192.554% |
| Suven Pharmaceuticals Limited | 10.51 Billion INR | -60.183% |
| Wockhardt Limited | 27.89 Billion INR | 39.617% |
| Themis Medicare Limited | 3.81 Billion INR | -341.136% |
| Jagsonpal Pharmaceuticals Limited | 2.08 Billion INR | -706.933% |
| Jubilant Pharmova Limited | 67.02 Billion INR | 74.875% |
| Glenmark Life Sciences Limited | 22.83 Billion INR | 26.241% |
| Dr. Reddy's Laboratories Limited | 279.16 Billion INR | 93.967% |
| Divi's Laboratories Limited | 78.45 Billion INR | 78.533% |
| NATCO Pharma Limited | 40.02 Billion INR | 57.919% |
| Gufic Biosciences Limited | 8.06 Billion INR | -108.771% |
| IOL Chemicals and Pharmaceuticals Limited | 21.18 Billion INR | 20.523% |
| Ind-Swift Limited | 5.02 Billion INR | -235.163% |
| Procter & Gamble Health Limited | 11.51 Billion INR | -46.282% |
| FDC Limited | 19.42 Billion INR | 13.323% |
| Krebs Biochemicals & Industries Limited | 504.21 Million INR | -3240.016% |
| Granules India Limited | 45.06 Billion INR | 62.629% |
| Medicamen Biotech Limited | 1.79 Billion INR | -839.224% |
| Alkem Laboratories Limited | 126.67 Billion INR | 86.706% |
| AstraZeneca Pharma India Limited | 12.95 Billion INR | -29.992% |
| Biofil Chemicals and Pharmaceuticals Limited | 400.35 Million INR | -4106.503% |
| Brooks Laboratories Limited | 794.86 Million INR | -2018.718% |
| Megasoft Limited | 373.95 Million INR | -4403.47% |
| ZIM Laboratories Limited | 3.67 Billion INR | -358.349% |
| Strides Pharma Science Limited | 40.51 Billion INR | 58.429% |
| Neuland Laboratories Limited | 15.58 Billion INR | -8.053% |
| Morepen Laboratories Limited | 17.01 Billion INR | 1.047% |
| Hikal Limited | 17.84 Billion INR | 5.632% |
| Indoco Remedies Limited | 17.89 Billion INR | 5.888% |
| Aarti Pharmalabs Limited | 18.15 Billion INR | 7.239% |
| Kilitch Drugs (India) Limited | 1.54 Billion INR | -990.924% |
| Mangalam Drugs & Organics Limited | 3.68 Billion INR | -356.894% |
| Hester Biosciences Limited | 3.04 Billion INR | -452.982% |